Status:
UNKNOWN
A Trial to Evaluate the Safety and PK Profile of HRS4800 in Healthy Subjects
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Pain
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The study will be conducted to evaluate the safety and PK profile of HRS4800 tablets after single oral administration in different dose levels compared to placebo.
Eligibility Criteria
Inclusion
- Able to understand the purposes and risks of the trial and comply with all study procedures before entering the trial, and provide signed informed consent.
- Male aged between 18 years and 55 years at screening, inclusive.
- Total body weight ≥50 kg at screening, and body mass index (BMI) between 19.0 and 26.0 kg/m2, inclusive.
- Agree to take contraceptive measures and promise not to donate sperm since signing the informed consent form, to 3 months after the administration.
- No clinically significant abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry, coagulation function), and ECG, as determined by the investigator.
Exclusion
- History of severe digestive system disease or having a digestive disease currently within 3 months of screening or before first dosing, and may affect drug absorption or have safety risks.
- Severe infections, injuries or surgeries within 3 months of screening or before first dosing, or plan to undergo any surgeries during the trial.
- ALT, AST, ALP or total bilirubin level exceeds the upper limit of normal (ULN) during screening/baseline visits.
- Subject's supine systolic BP is ≥140 mmHg or \<90 mmHg; diastolic BP ≥90 mmHg or \<60 mmHg at screening or before first dosing.
- Positive breath alcohol test after confirmation in a repeat test during screening/baseline visits.
- Positive drug screening tests,.
- Whole blood donation or loss of more than 200 mL of blood within 1 month prior to dosing; or blood donation or loss of more than 400 mL of blood within 3 months prior to dosing; or received blood within 2 months prior to dosing.
- History of allergy to the study drug or any component of it.
Key Trial Info
Start Date :
May 3 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 24 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04862884
Start Date
May 3 2021
End Date
September 24 2021
Last Update
April 28 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.